|
| Press Releases |
|
 |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
| Monday, June 5, 2017 |
|
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
|
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab |
| Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate in combination with the MSD anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA), during a presentation at the 53rd Annual Meeting of ASCO. more info >> |
|
| Thursday, June 1, 2017 |
|
|
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities |
| Eisai Co., Ltd. has announced that it will grant a total of 500 million yen to the Global Health Innovative Technology Fund (GHIT Fund) to fund the second phase of its activities, which will take place in the five-year period from FY 2018 to FY 2022. more info >> |
|
| Wednesday, May 31, 2017 |
|
|
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine |
| Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new antimalarial medicine based on antimalarial drug targets the team identified last year. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate and eribulin mesylate, as well as H3B-8800 will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). more info >> |
|
| Wednesday, April 19, 2017 |
|
|
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis |
| Eisai Co., Ltd. has announced the results of its initiatives for the elimination of lymphatic filariasis (LF), and its continued support of this cause in the future. more info >> |
|
| Tuesday, April 11, 2017 |
|
|
Eisai to Launch "Chocola BB Gold Rich" Highest Combination of Active Ingredients in Chocola BB Series |
| Eisai Co., Ltd. announced today that, approaching the 65th anniversary of its Chocola BB brand, it will launch Chocola BB Gold Rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on Monday, April 17. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Magnolia Welcomes Tech Pioneer Luc Haldimann as New Board Chairman to Expand Global Growth and AI Strategy
Nov 28, 2025 00:00 HKT/SGT
|
|
|
NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST
|
|
|
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Interim Results
Nov 27, 2025 18:43 HKT/SGT
|
|
|
PLN Collaborates with Norwegian and Japanese Stakeholders to Advance High-Integrity Cross-Border Carbon Markets at COP30 
Nov 27, 2025 18:30 HKT/SGT
|
|
|
Geespace Accelerates Global Expansion as GEESATCOM Enters New Markets
Nov 27, 2025 15:30 HKT/SGT
|
|
|
KEF, the premium speaker brand of Gold Peak, partners with Huawei to unlock new wireless high-fidelity experience with HUAWEI HiPlay
Nov 27, 2025 13:29 HKT/SGT
|
|
|
World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST
|
|
|
CBL International Limited Wins Prestigious 'CGMA Excellent Sustainability Award' at the CGMA Annual Awards 2025
Nov 26, 2025 18:54 HKT/SGT
|
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST
|
|
|
Fujitsu accelerates blue carbon certification with ocean digital twin technology
Nov 26, 2025 19:05 JST
|
|
|
Fujitsu recognized with two Microsoft Japan Partner of the Year awards
Nov 26, 2025 18:40 JST
|
|
|
Xforce HEV Model Wins Thailand Car of the Year 2025
Nov 26, 2025 18:00 JST
|
|
|
New micromobility concepts for increased sustainability in urban traffic: BMW Group grants licenses to the LUYUAN Group
Nov 26, 2025 13:01 HKT/SGT
|
|
|
Stage set for DesignInspire with VIP preview on 3 December and free entry for industry and public over next three days
Nov 26, 2025 11:40 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
